ArticleSignal transduction and targeted therapy2026
Targeting N
Article in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Osteoporosis is among the most common degenerative systemic bone diseases and is accompanied by abnormally downregulated oxidative phosphorylation (OXPHOS) in osteoblasts. While mutations in the tRNA methyltransferase (TRMT10C) gene in humans are known to cause OXPHOS dysfunction and early mortality, its role in bone homeostasis remains unknown. Here, we observed markedly reduced expression of TRMT10C, which is encoded by the nuclear genome, and OXPHOS subunits, which are encoded by the mitochondrial (mt) genome, in osteoblasts from both age-related and estrogen deficiency-induced osteoporosis mice. Conditional knockout of Trmt10c in osterix-expressing osteoprogenitor cells resulted in growth retardation, bone loss, and spontaneous fractures. Critically, through a multistage in silico screening approach, we identified a novel small-molecule compound as a TRMT10C agonist for the first time. Pharmacological activation of TRMT10C by this compound significantly promoted bone formation and ameliorated osteoporotic phenotypes in both aged and ovariectomized mice. Mechanistically, this study provides the first evidence that TRMT10C can bind to and catalyze the N
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.